MARTIN AND HARRIS LABORATORIES LIMITED UNLISTED SHARE
ABOUT MARTIN AND HARRIS LABORATORIES LIMITED
MARTIN AND HARRIS LABORATORIES LIMITED was first established in 1996 and is based in Gurgaon, Haryana. The company is a part of Apeejay Group, which is India’s oldest and largest Conglomerates. Apeejay Group is a leading Industrial & Investment house with businesses in Automotive, Chemicals & Plastics, Distribution, Logistics & Retail, Pharmaceuticals & life sciences, real estate, and international trading and a nascent presence in IT, merchant banking & financial services and publishing.
Martin and Harris Laboratories Limited is primarily engaged in the business of manufacturing pharmaceuticals, medicinal chemicals & botanical products. The company intensively focuses on drugs used for Hyper Tension, High blood pressure, and heart attack. Apart from its primary business, the company also undertakes fund management through investment in different avenues like mutual funds, equity, etc.
Martin and Harris Laboratories Limited has two units located at Roorkee, Uttarakhand, and Una in Himachal Pradesh. The company is continuously striving to expand its manufacturing facilities and meet global standards.
The company was awarded ‘Best Pharma Excellence awards’ in 2018 by ASSOCHAM India.
INCORPORATION DETAILS
|
CIN |
U24239HR1993PLC033630 |
|
Registration Date |
22 July 1993 |
|
Category/Sub-category of the Company |
Company Limited by Shares |
|
Address of the Registered office and contact details |
NH-8, Delhi Jaipur Highway, Village, Pachgaon (Fazalwas), District Gurgaon, Haryana |
|
Name, Address and Contact Details of Registrar and Transfer Agent, if any |
NA |
PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
|
Name and Description of main products/services |
NIC Code of the product/service |
% to total turnover of the Company |
|
Manufacture of Pharmaceutical, Medicinal Chemical & Botanical Products |
210 |
52.03% |
|
Fund management activities |
663 |
47.97% |
BOARD OF DIRECTORS
MR. S. L. LAAD
MR. G. K. NIGAM
MR. AJAY GROVER
MR. H. S. THAKUR
PARTICULARS OF SUBSIDIARY COMPANIES
|
Name of the Company |
% of shares held |
|
Delite Infrastructure Private limited |
100.00% |
MARTIN AND HARRIS LABORATORIES LIMITED UNLISTED SHARE DETAILS
|
Total Available Shares: |
39,96,040 |
|
Face Value: |
Rs. 10 Per Equity Share |
|
ISIN: |
INE03VV01015 |
|
PAN No.: |
AABCM0832A |
|
Lot Size: |
50 Shares |
|
Last Traded Price: |
Rs. 1800 |
|
Market Cap: |
Rs. 719.29 Crore |
SHAREHOLDING PATTERN
(As on 31-03-2020)
|
S. No. |
Shareholders’ Name |
Number of shares |
% of total Shares of the company |
|
1 |
Promoters Shareholding |
140 |
0.004% |
|
2 |
Public Shareholding |
39,95,900 |
99.996% |
|
|
Total |
39,96,040 |
100.00% |
INDUSTRY OUTLOOK
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability has helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
KEY FINANCIALS OF MARTIN AND HARRIS LABORATORIES LIMITED(In Rs. Lakhs)
|
Particulars |
2020 |
2019 |
2018 |
2017 |
|
Revenue from Operations |
26,729.47 |
24,723.47 |
16,655.48 |
13,448.93 |
|
EBITDA |
6,385.87 |
5,108.93 |
7,073.97 |
4,032.14 |
|
EBITDA margin |
23.89% |
20.66% |
42.47% |
29.98% |
|
Finance Cost |
25.04 |
7.36 |
19.26 |
142.89 |
|
Depreciation |
156.22 |
164.73 |
133.49 |
137.24 |
|
Other Income |
2,937.53 |
4,267.03 |
1,082.88 |
260.26 |
|
Profit Before Tax |
9,142.15 |
9,203.87 |
8,004.11 |
4,012.27 |
|
Total Tax |
2,220.50 |
1,959.86 |
2,066.32 |
1,118.53 |
|
Profit After Tax (PAT) |
6,921.65 |
7,244.01 |
5,937.79 |
2,893.74 |
|
EPS |
173.21 |
181.28 |
148.59 |
72.42 |
BALANCE SHEET OF MARTIN AND HARRIS LABORATORIES LIMITED(In Rs. Lakhs)
|
Particulars |
2020 |
2019 |
|
ASSETS |
||
|
NON CURRENT ASSETS |
||
|
Tangible assets |
5,530.50 |
4693.41 |
|
Investments |
25,736.37 |
4178.87 |
|
TOTAL NON CURRENT ASSETS |
31,266.87 |
8,872.28 |
|
CURRENT ASSETS |
||
|
Inventories |
2,058.24 |
1,021.08 |
|
Trade Receivables |
1,844.65 |
563.40 |
|
Cash and Cash Equivalents |
77.85 |
59.25 |
|
Short-Term Loans and Advances |
1,385.53 |
16,762.58 |
|
Other Current Assets |
18.73 |
17.83 |
|
TOTAL CURRENT ASSETS |
5,384.99 |
18,424.13 |
|
TOTAL ASSETS |
36,651.86 |
27,296.41 |
|
EQUITY AND LIABILITIES |
||
|
EQUITY |
||
|
Share capital |
399.60 |
399.60 |
|
Reserves and Surplus |
32,254.02 |
25,443.64 |
|
TOTAL EQUITY |
32,653.63 |
25,843.25 |
|
LIABILITIES |
||
|
NON CURRENT LIABILITIES |
||
|
Long Term Borrowings |
460.61 |
456.62 |
|
Deferred Tax Liabilities (Net) |
61.39 |
66.73 |
|
TOTAL NON CURRENT LIABILITIES |
522.00 |
523.35 |
|
CURRENT LIABILITIES |
||
|
Short Term Borrowings |
920.75 |
1.08 |
|
Trade Payables |
1,773.14 |
499.01 |
|
Other Current Liabilities |
1.95 |
0.84 |
|
Short-Term Provisions |
780.41 |
428.89 |
|
TOTAL CURRENT LIABILITIES |
3,476.24 |
929.81 |
|
TOTAL LIABILITIES |
3,998.23 |
1,453.16 |
|
TOTAL EQUITY AND LIABILITIES |
36,651.86 |
27,296.41 |
DIVIDEND HISTORY
|
Particulars |
2020 |
2019 |
2018 |
|
Dividend (final + interim) (In Rs.) |
2.20 |
2.20 |
1.8 |
PERFORMANCE OF THE COMPANY
Revenue from Operations of the company increased by 8% from Rs. 24,723.47 lakhs in FY 2019 to Rs. 26,729.47 lakhs in FY 2020.
EBITDA of the company increased by 25% from Rs. 5,108.93 lakhs in FY 2019 to Rs. 6,385.87 lakhs in FY 2020. EBITDA margin of the company increased from 20.66% in FY 2019 to 23.89% in FY 2020.
Profit after tax of the company decreased by 4% from Rs. 7,244.01 lakhs in FY 2019 to Rs. 6,921.65 lakhs in FY 2020.
The current ratio of the company as of 31st March 2020 was 1.54.
The debt to equity ratio of the company as of 31st March 2020 was 0.04. The company is almost a debt-free company.
Return on Equity for the company for FY 2020 was 21.19%.
Book value per equity share of the company as of 31st march 2020 was Rs. 817.14.
Martin and Harris Laboratories Limited has consistently given dividends for the past three years. For FY 2020, the company has given a dividend of Rs. 2.20.
